<![CDATA[Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg]]>
Antibody-drug conjugates (ADCs) have become increasingly relevant in cancer care over the past decade, with 2 FDA approvals in 2025 shedding light on their growing role in lung cancer.1-3 ADCs consist of three components: an antibody that binds to tumor …